公开(公告)号：NZ213717A

公开(公告)日：1989-01-06

申请号：NZ21371785

申请日：1985-10-04

Applicant: HOECHST AG

Inventor： ENGELS J ,  LEINEWEBER M ,  UHLMANN E ,  WETEKAM W

IPC: C12N15/09 ,  C07H21/04 ,  C07K14/62 ,  C12N1/20 ,  C12N15/62 ,  C12P21/00 ,  C12R1/19 ,  C12N15/00

公开(公告)号：NZ211478A

公开(公告)日：1988-10-28

申请号：NZ21147885

申请日：1985-03-18

Applicant: HOECHST AG

Inventor： ENGELS J ,  LEINEWEBER M ,  UHLMANN E ,  ULMAR W

IPC: C12N15/09 ,  A61K38/21 ,  C07H21/04 ,  C07K1/22 ,  C07K14/52 ,  C07K14/555 ,  C07K14/57 ,  C07K16/00 ,  C12N1/20 ,  C12P21/02 ,  C12R1/19 ,  C12N15/00 ,  C12P21/00 ,  A61K45/02

Abstract: A specific DNA sequence can be used in the process to obtain human gamma -interferon. The gene is advantageously synthesised in the form of several fragments which are enzymatically ligated to give larger part-sequences which are incorporated into hybrid plasmids and amplified in host organisms. The part-sequences are reisolated and then combined to give the complete gene, which is incorporated into a hybrid plasmid, and the latter is expressed in a host organism.

公开(公告)号：NZ215858A

公开(公告)日：1989-01-06

申请号：NZ21585886

申请日：1986-04-17

Applicant: HOECHST AG

Inventor： ENGELS J ,  LEINEWEBER M ,  UHLMANN E ,  WENGENMAYER F

IPC: C12N15/09 ,  C07K14/55 ,  C12N1/20 ,  C12N9/86 ,  C12N15/00 ,  C12N15/67 ,  C12N15/71 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C07H21/04

Abstract: For the contracting states : BE, CH, DE, GB, IT, LI, LU, NL, SE 1. DNA segment of the trp operon from E. coli, characterized by the sequence (coding strand) I 5' CTATCGACC 3' (I) which is connected at the 5' end to the Shine-Dalgarno sequence AAGG, and at the 3' end to the start codon ATG. For the contracting state : AT 1. A process for the preparation of a vector having the trp expression system of E. coli, characterized by cleavage with the restriction enzyme Nco l of an E. coli vector which contains the DNA sequence I 5' GTATCGACC 3' (I) (coding strand) followed by 5' ATGG 3', and a) ligation of a gene structure of DNA sequence II 5' CATG X... 3' 3' Y... 5' (II) in which X and Y denote the first complementary pair of nucleotides downstream of the start codon of a structural gene, in the cleavage site, or b) enzymatic filling in of the cleavage site and ligation of the DNA of the sequence III 5' GTA TCG ACC ATG 3' (III) 3' CAT AGC TGG TAC 5' with a DNA of the sequence IV 5' X... 3' (IV) 3' Y... 5' in which X and Y have the abovementioned meaning, or c) enzymatic degradation of the protruding sequence of the cleavage site, and ligation of the DNA of the sequence VI 5' GTA TCG AC 3' (VI) 3' CAT AGC TG 5' with a DNA of the sequence VII 5' Z ATG X... 3' (VII) 3' Z'TAC Y... 5' Z and Z' denoting any desired pair of nucleotides, which can also be dispensed with.

公开(公告)号：NZ211827A

公开(公告)日：1988-07-28

申请号：NZ21182785

申请日：1985-04-17

Applicant: HOECHST AG

Inventor： ENGELS J ,  LEINEWEBER M ,  UHLMANN E ,  ULMER W

IPC: A61K38/21 ,  A61K38/00 ,  C07H21/04 ,  C07K1/22 ,  C07K14/52 ,  C07K14/555 ,  C07K14/57 ,  C07K16/00 ,  C12N1/20 ,  C12N1/21 ,  C12N15/00 ,  C12N15/09 ,  C12P19/34 ,  C12P21/02 ,  C12R1/19 ,  C07K15/26 ,  C07K7/10 ,  A61K45/02

Abstract: Partial sequences of human- gamma -interferon, comprising aminoacid sequences 5 to 127, 1 to 127 and 5 to 146, having biological activity. These partial sequences can be obtained by a genetic engineering process, for which purpose the appropriate DNA sequences are chemically synthesized. The DNA sequences are incorporated in hybrid plasmids, and the latter are introduced into host organisms and their expression is induced there. The biologically active polypeptides are suitable, as is human- gamma -interferon, for medicaments.

公开(公告)号：NZ217994A

公开(公告)日：1988-09-29

申请号：NZ21799486

申请日：1986-10-20

Applicant: HOECHST AG

Inventor： ENGELS J ,  UHLMANN E ,  WENGENMAYER F ,  MULLNER H ,  LEINEWEBER M ,  WINNACKER E-L ,  MERTZ R

IPC: C12N15/09 ,  A61K38/00 ,  C07K14/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/55 ,  C12P21/02 ,  C07K15/08 ,  C12N15/00 ,  C12N1/20 ,  C12P21/00

Abstract: Proteins whose amino-acid sequence essentially corresponds to that of natural interleukin-2 (IL-2) but which lacks the first 7 N-terminal amino acids display the biological activity of IL-2. These proteins can be prepared by genetic manipulation. They are suitable for the preparation of pharmaceuticals with IL-2 activity.

公开(公告)号：NZ213049A

公开(公告)日：1988-05-30

申请号：NZ21304985

申请日：1985-08-08

Applicant: HOECHST AG

Inventor： BRAUER D ,  ENGELS J ,  HABERMANN P ,  UHLMANN E ,  WENGENMAYER F

IPC: C12N15/09 ,  A61K38/00 ,  C07H21/00 ,  C07H21/04 ,  C07K14/00 ,  C07K14/435 ,  C07K14/815 ,  C12N1/20 ,  C12N15/00 ,  C12N15/62 ,  C12N15/72 ,  C12P19/34 ,  C12P21/02 ,  C12R1/19 ,  C07K7/10

Abstract: Hirudin can be obtained using a specific DNA sequence in a genetic engineering process. The gene is advantageously synthesised in the form of several fragments which are enzymatically ligated to give two larger part-sequences which are incorporated into hybrid plasmids and amplified in host organisms. The part-sequences are reisolated and then combined to form the complete gene which is incorporated into a hybrid plasmid and the latter is expressed in a host organism.